Drugs News and Research

RSS

First Edition: April 6, 2012

Today's early morning highlights from the major news organizations, including the Obama administration's response to a federal court about the Supreme Court's power.

6 Apr 2012

Poultry producers still use FDA-banned antibiotics

In a joint study, researchers at the Johns Hopkins Bloomberg School of Public Health and Arizona State University found evidence suggesting that a class of antibiotics previously banned by the U.S. government for poultry production is still in use. Results of the study were published March 21 in Environmental Science & Technology.

6 Apr 2012

Ohio AIDS advocates, patients protest against rationing of lifesaving HIV medicines

A group of Ohio AIDS advocates, patients and medical providers hosted a protest in Columbus today in conjunction with a public hearing held by the Ohio Department of Health (ODH) and its Director, Theodore E. Wymyslo, M.D., on proposed rule changes that would restrict access to lifesaving AIDS drugs for low-income Ohioans based on medical criteria.

6 Apr 2012

Regeneron, Sanofi announce clinical and regulatory update for ZALTRAP

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review of the Biologics License Application (BLA) for the investigational agent ZALTRAP (aflibercept) concentrate for solution for infusion in combination with the irinotecan-fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer (mCRC) previously treated with an oxaliplatin-containing regimen.

6 Apr 2012

Methylphenidate may help induce recovery from propofol anesthesia

The ability of the commonly used stimulant methylphenidate (Ritalin) to speed recovery from general anesthesia appears to apply both to the inhaled gas isoflurane, as previously reported, and to the intravenous drug propofol. Members of the same Massachusetts General Hospital (MGH) research team that reported the isoflurane study are publishing similar results for propofol in the May issue of Anesthesiology, and their paper has been issued online.

6 Apr 2012

U.S. spending on prescription drugs, doctor visits levels off

A study by the IMS Institute for Healthcare Informatics found that seniors citizens especially are filling fewer prescriptions as out-of-pocket costs increase.

6 Apr 2012

Viewpoints: Support for drug benefit merger; Health reform comes too slowly for some patients; Pinpointing Romney's views on mandate

It seems counterintuitive, but the Federal Trade Commission has just decided that a $29 billion merger of two of the three largest companies that manage pharmaceutical benefits for employers and health plans - Express Scripts and Medco Health Solutions - would not substantially lessen competition. That judgment deserves credence because of the thoroughness of the F.T.C.'s eight-month inquiry and the willingness of the agency to oppose other mergers when the evidence warrants.

6 Apr 2012

State roundup: Advocates in Va. back shifting disability care from state institutions; New Vt. law overhauls mental health system; Aetna mistakenly tells thousands in Calif. their doctors were dropped

A state agency that looks out for the rights of people with disabilities is advocating for a proposed settlement that would shift the care of Virginians with intellectual disabilities from state-run institutions.

6 Apr 2012

Positive effect of tafamidis on neurological degeneration

Tafamidis meglumine was approved in November 2011 for the treatment of transthyretin amyloidosis in adults. This rare disorder is caused by a defective gene and is associated with progressive nerve damage (neurological degeneration) that tafamidis is supposed to delay.

6 Apr 2012

Researchers develop new technique to grow stem cells

Post-doctoral researcher David Fluri and Professor Peter Zandstra at the University of Toronto's Institute of Biomaterials and Biomedical Engineering (IBBME) have developed a unique new technique for growing stem cells that may make possible cost-effective, large-scale stem cell manufacturing and research.

6 Apr 2012

Astellas' mirabegron for OAB receives FDA advisory committee approval

Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc., announced today that the Reproductive Health Drugs Advisory Committee of the U.S. Food and Drug Administration voted that the overall risk/benefit assessment supports approval of mirabegron for the treatment of overactive bladder.

6 Apr 2012

Spectrum’s apaziquone Phase 3 trials on bladder cancer do not meet primary endpoint

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that the two double blind, randomized, placebo controlled, Phase 3 clinical trials for apaziquone did not meet their primary endpoint of a statistically significant difference in the rate of tumor recurrence at 2 years between the two arms.

6 Apr 2012

TAM protein complex - a potential antibacterial target

Scientists could produce new antibacterial treatments by disarming the molecular pumps bacteria use to bring disease causing molecules in contact with animals and humans.

6 Apr 2012

Towards a drug to control cystic fibrosis

Harvard stem cell researchers at Massachusetts General Hospital (MGH) have taken a critical step in making possible the discovery in the relatively near future of a drug to control cystic fibrosis (CF), a fatal lung disease that claims about 500 lives each year, with 1,000 new cases diagnosed annually.

6 Apr 2012

Ameritox, Ridge Diagnostics partner to develop MDDScore test

Ridge Diagnostics, Inc., a neurodiagnostic company, announced today it has entered into an exclusive agreement with Ameritox, Ltd., a leader in medication monitoring, for the license rights to its proprietary developmental blood test MDDScore, a multiple biomarker analysis for Major Depressive Disorder (MDD) for primary care and pain physicians.

6 Apr 2012

African-Americans and Hispanics with MDD less likely to get antidepressants

African-Americans and Hispanics with major depressive disorder are less likely to get antidepressants than Caucasian patients, and Medicare and Medicaid patients are less likely to get the newest generation of antidepressants.

6 Apr 2012

Spectrum signs definitive agreement to acquire Allos

Spectrum Pharmaceuticals and Allos Therapeutics, Inc. today announced that they have signed a definitive agreement under which Spectrum will acquire all of the outstanding shares of Allos for $1.82 per share in cash plus one Contingent Value Right.

6 Apr 2012

Doctors continue to prescribe dangerous nifedipine drug to elderly patients

Despite the fact that nifedipine increases the risk of heart attacks and death, doctors still prescribe this immediate-release blood pressure drug to elderly patients. The Cologne-based research group led by Ingrid Schubert has now published the results of their investigation in the current issue of Deutsches -rzteblatt International.

6 Apr 2012

Weight loss pill Qnexa wins panel vote and awaits approval

The drug was rejected in a 10-6 vote the first time it came before a Food and Drug Administration (FDA) advisory panel, in 2010, due to safety concerns. However when the medication returned for another review in February, the advisory committee gave it near-unanimous approval (20-2). Because the FDA often follows the advisory panel's advice, Qnexa is likely to get FDA approval, probably by mid-April.

5 Apr 2012

PTSD could be genetically predicted

PTSD can occur after any kind of experience that causes trauma, whether that be in war, after a natural disaster or because of child abuse or sexual assault. Symptoms can include flashbacks, feeling emotionally numb or hyper-alert to danger, and avoiding situations that act as reminders of the original trauma. It is estimated that up to 3% of the general population is likely to be affected by PTSD at some point.

5 Apr 2012